GB201202319D0 - Stromal stem cells - Google Patents

Stromal stem cells

Info

Publication number
GB201202319D0
GB201202319D0 GBGB1202319.8A GB201202319A GB201202319D0 GB 201202319 D0 GB201202319 D0 GB 201202319D0 GB 201202319 A GB201202319 A GB 201202319A GB 201202319 D0 GB201202319 D0 GB 201202319D0
Authority
GB
United Kingdom
Prior art keywords
stem cells
stromal stem
stromal
cells
stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1202319.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orbsen Therapeutics Ltd
Original Assignee
Orbsen Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orbsen Therapeutics Ltd filed Critical Orbsen Therapeutics Ltd
Priority to GBGB1202319.8A priority Critical patent/GB201202319D0/en
Publication of GB201202319D0 publication Critical patent/GB201202319D0/en
Priority to CN201380019351.0A priority patent/CN104302763B/zh
Priority to HRP20150594TT priority patent/HRP20150594T1/hr
Priority to ES13707295.5T priority patent/ES2539186T3/es
Priority to EP18190005.1A priority patent/EP3492584B1/en
Priority to CA2863821A priority patent/CA2863821C/en
Priority to SI201330036T priority patent/SI2758523T1/sl
Priority to EP23176834.2A priority patent/EP4257203A3/en
Priority to PL13707295T priority patent/PL2758523T3/pl
Priority to KR1020147025152A priority patent/KR102124837B1/ko
Priority to ES15158384T priority patent/ES2697780T3/es
Priority to EP13707295.5A priority patent/EP2758523B1/en
Priority to DK13707295.5T priority patent/DK2758523T3/da
Priority to RS20150392A priority patent/RS54073B1/en
Priority to JP2014556093A priority patent/JP5829765B2/ja
Priority to RU2014136711A priority patent/RU2636551C2/ru
Priority to BR112014019277A priority patent/BR112014019277A8/pt
Priority to US14/377,597 priority patent/US11230700B2/en
Priority to ES18190005T priority patent/ES2959833T3/es
Priority to AU2013217870A priority patent/AU2013217870B2/en
Priority to HUE13707295A priority patent/HUE026480T2/en
Priority to EP15158384.6A priority patent/EP2902482B1/en
Priority to PCT/EP2013/052692 priority patent/WO2013117761A1/en
Priority to PT137072955T priority patent/PT2758523E/pt
Priority to IN1777KON2014 priority patent/IN2014KN01777A/en
Priority to CY20151100502T priority patent/CY1116365T1/el
Priority to SM201500147T priority patent/SMT201500147B/xx
Priority to US15/089,435 priority patent/US10907131B2/en
Priority to US16/009,048 priority patent/US11142747B2/en
Priority to US16/562,206 priority patent/US10920197B2/en
Priority to US17/470,492 priority patent/US11926848B2/en
Priority to US17/540,067 priority patent/US11434471B2/en
Priority to US18/329,455 priority patent/US11952589B2/en
Priority to US18/329,435 priority patent/US11884936B2/en
Priority to US18/329,469 priority patent/US11952590B2/en
Priority to US18/599,002 priority patent/US20240209319A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
GBGB1202319.8A 2012-02-10 2012-02-10 Stromal stem cells Ceased GB201202319D0 (en)

Priority Applications (36)

Application Number Priority Date Filing Date Title
GBGB1202319.8A GB201202319D0 (en) 2012-02-10 2012-02-10 Stromal stem cells
AU2013217870A AU2013217870B2 (en) 2012-02-10 2013-02-11 Stromal stem cells
BR112014019277A BR112014019277A8 (pt) 2012-02-10 2013-02-11 Populações de células-tronco estromais, tecidos, métodos de isolamento de células-tronco estromais, método de obtenção de tecido, ensaio e método para condução de ensaio e composição farmacêutica
HRP20150594TT HRP20150594T1 (hr) 2012-02-10 2013-02-11 Stromalne matiäśne stanice
ES13707295.5T ES2539186T3 (es) 2012-02-10 2013-02-11 Células madre estromales
EP18190005.1A EP3492584B1 (en) 2012-02-10 2013-02-11 Methods of obtaining stromal stem cells
CA2863821A CA2863821C (en) 2012-02-10 2013-02-11 Stromal stem cells expressing syndecan-2
SI201330036T SI2758523T1 (sl) 2012-02-10 2013-02-11 Stromalne matične celice
EP23176834.2A EP4257203A3 (en) 2012-02-10 2013-02-11 Methods of obtaining stromal stem cells
PL13707295T PL2758523T3 (pl) 2012-02-10 2013-02-11 Zrębowe komórki macierzyste
KR1020147025152A KR102124837B1 (ko) 2012-02-10 2013-02-11 기질 줄기 세포
ES15158384T ES2697780T3 (es) 2012-02-10 2013-02-11 Métodos para obtener células madre estromales
EP13707295.5A EP2758523B1 (en) 2012-02-10 2013-02-11 Stromal stem cells
DK13707295.5T DK2758523T3 (da) 2012-02-10 2013-02-11 Stromastamceller
RS20150392A RS54073B1 (en) 2012-02-10 2013-02-11 STROMAL MATERIAL CELLS
JP2014556093A JP5829765B2 (ja) 2012-02-10 2013-02-11 間質幹細胞
RU2014136711A RU2636551C2 (ru) 2012-02-10 2013-02-11 Стромальные стволовые клетки
CN201380019351.0A CN104302763B (zh) 2012-02-10 2013-02-11 基质干细胞
ES18190005T ES2959833T3 (es) 2012-02-10 2013-02-11 Métodos para obtener células madre estromales
US14/377,597 US11230700B2 (en) 2012-02-10 2013-02-11 Stromal stem cells
PT137072955T PT2758523E (pt) 2012-02-10 2013-02-11 Células estaminais estromais
HUE13707295A HUE026480T2 (en) 2012-02-10 2013-02-11 Stromal stem cells
EP15158384.6A EP2902482B1 (en) 2012-02-10 2013-02-11 Methods of obtaining stromal stem cells
PCT/EP2013/052692 WO2013117761A1 (en) 2012-02-10 2013-02-11 Stromal stem cells
IN1777KON2014 IN2014KN01777A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-02-10 2014-08-22
CY20151100502T CY1116365T1 (el) 2012-02-10 2015-06-08 Στρωματικα βλαστικα κυτταρα
SM201500147T SMT201500147B (it) 2012-02-10 2015-06-25 Cellule staminali stromalo
US15/089,435 US10907131B2 (en) 2012-02-10 2016-04-01 Stromal stem cells
US16/009,048 US11142747B2 (en) 2012-02-10 2018-06-14 Stromal stem cells
US16/562,206 US10920197B2 (en) 2012-02-10 2019-09-05 Stromal stem cells
US17/470,492 US11926848B2 (en) 2012-02-10 2021-09-09 Stromal stem cells
US17/540,067 US11434471B2 (en) 2012-02-10 2021-12-01 Stromal stem cells
US18/329,455 US11952589B2 (en) 2012-02-10 2023-06-05 Stromal stem cells
US18/329,435 US11884936B2 (en) 2012-02-10 2023-06-05 Stromal stem cells
US18/329,469 US11952590B2 (en) 2012-02-10 2023-06-05 Stromal stem cells
US18/599,002 US20240209319A1 (en) 2012-02-10 2024-03-07 Stromal stem cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1202319.8A GB201202319D0 (en) 2012-02-10 2012-02-10 Stromal stem cells

Publications (1)

Publication Number Publication Date
GB201202319D0 true GB201202319D0 (en) 2012-03-28

Family

ID=45929927

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1202319.8A Ceased GB201202319D0 (en) 2012-02-10 2012-02-10 Stromal stem cells

Country Status (22)

Country Link
US (10) US11230700B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (4) EP3492584B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP5829765B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102124837B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104302763B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013217870B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014019277A8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2863821C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1116365T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2758523T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES2959833T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB201202319D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20150594T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE026480T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014KN01777A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2758523T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2758523E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS54073B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2636551C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2758523T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SM (1) SMT201500147B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013117761A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
AU2014255755B2 (en) 2013-04-16 2018-10-25 Orbsen Therapeutics Limited Medical use of syndecan-2
US20170044497A1 (en) 2014-02-12 2017-02-16 National University Of Ireland, Galway Selection and use of stem cells
KR101690872B1 (ko) 2014-08-19 2016-12-29 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포로부터 인슐린 분비 세포의 분화 방법
US9716660B2 (en) * 2014-12-11 2017-07-25 Intel Corporation Hierarchical enforcement of service flow quotas
KR101686315B1 (ko) 2015-01-09 2016-12-13 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포로부터 슈반 세포의 분화 방법
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2016154019A1 (en) * 2015-03-20 2016-09-29 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
US11918687B2 (en) * 2016-01-15 2024-03-05 Orbsen Therapeutics Limited SDC-2 exosome compositions and methods of isolation and use
CN106177918A (zh) * 2016-09-30 2016-12-07 广州赛莱拉干细胞科技股份有限公司 一种间充质干细胞注射液及其制备方法和应用
US20210154235A1 (en) * 2017-05-30 2021-05-27 Orbsen Therapeutics Limited Stromal stem cell therapeutics and methods of use
WO2019012334A2 (en) * 2017-07-14 2019-01-17 Orbsen Therapeutics Limited METHODS OF ISOLATION AND USE OF CD39 STROMAL STEM CELLS
US12116418B2 (en) * 2019-09-23 2024-10-15 The Trustees Of The University Of Pennsylvania Disrupting tumor tissues by targeting fibroblast activation protein (FAP)
US12139550B2 (en) 2019-09-23 2024-11-12 The Trustees Of The University Of Pennsylvania Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (FAP)
WO2022179518A1 (en) * 2021-02-25 2022-09-01 Rosas Ivan O Anti-fibrotic peptides and uses thereof
CN116334214A (zh) * 2023-04-04 2023-06-27 暨南大学附属第一医院（广州华侨医院） 一种用于急性心肌梗死和稳定性心绞痛鉴别的生物标志物的ceRNA调控网络及其应用
IT202300007497A1 (it) * 2023-04-18 2024-10-18 Comecer Spa Isolatore per colture cellulari derivate da un tessuto perinatale e metodo di isolamento di almeno una tipologia di cellule da un tessuto perinatale

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1012403A (en) 1911-01-23 1911-12-19 Thomas W Mcneill Smoke-indicator.
US5486599A (en) 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5726058A (en) 1992-12-01 1998-03-10 Jalkanen; Markku Syndecan stimulation of cellular differentiation
AU2340397A (en) 1996-03-21 1997-10-10 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
ES2237089T3 (es) * 1998-03-13 2005-07-16 Osiris Therapeutics, Inc. Usos para celulas madre mesenquimatosas humanas no autologas.
ES2292245T3 (es) 1998-05-29 2008-03-01 Osiris Therapeutics, Inc. Celulas madre mesenquimaticas cd45+ y/o fibroblasto+humanas.
WO2001080865A2 (en) 2000-04-25 2001-11-01 Osiris Therapeutics, Inc. Joint repair using mesenchymal stem cells
US7442390B2 (en) * 2000-06-05 2008-10-28 University Of South Florida Method for enhancing engraftment of cells using mesenchymal progenitor cells
WO2002087609A1 (en) 2001-05-01 2002-11-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Identification of a cell surface receptor for papillomaviruses
CA2468292A1 (en) 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
US20030225018A1 (en) 2002-01-18 2003-12-04 Ekker Stephen C. Syndecans and angiogenesis
AU2003236557B2 (en) 2002-06-27 2009-10-01 Verva Pharmaceuticals Pty Ltd Differentiation modulating agents and uses therefor
JP4672370B2 (ja) * 2002-12-05 2011-04-20 ケース ウエスタン リザーブ ユニバーシティ 虚血の細胞ベースの治療
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
CA2564679C (en) 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
NZ553695A (en) * 2004-08-16 2009-10-30 Cellres Corp Pte Ltd Isolation of stem/progenitor cells from amniotic membrane of umbilical cord
US20060045872A1 (en) * 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
WO2007122823A1 (ja) 2006-04-20 2007-11-01 Jichi Medical University ベクター産生型腫瘍標的細胞
US20070264239A1 (en) 2006-05-10 2007-11-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Isolation of pericytes
WO2008085229A2 (en) 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
KR100883565B1 (ko) 2007-02-14 2009-02-13 (주)프로스테믹스 지방 줄기세포의 조직 재생 능력을 최적화한 조건 배지를 함유한 조직 재생용 주사제 첨가제
KR20080103637A (ko) * 2007-05-25 2008-11-28 주식회사 알앤엘바이오 지방유래 줄기세포를 함유하는 사지말단부 허혈성 질환의세포치료용 조성물
WO2009012357A2 (en) 2007-07-17 2009-01-22 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
DK2205721T3 (en) 2007-10-17 2016-10-24 Txcell TR1 cells mesenchymal stem cells and uses thereof
KR20100112192A (ko) * 2008-02-04 2010-10-18 바이파 사이언스 인코포레이티드 Ｐａｒｐ－매개된 질병을 진단 및 치료하는 방법
US20090220588A1 (en) 2008-02-21 2009-09-03 Massachusetts Institute Of Technology Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity
WO2010065239A1 (en) 2008-12-05 2010-06-10 Wake Forest University Health Sciences Stem cells from urine and methods for using the same
KR20100106744A (ko) 2009-03-24 2010-10-04 이화여자대학교 산학협력단 이동성 피부세포질환 또는 멜라닌 합성관련 질환 예방 또는치료용 조성물
CA2758120C (en) 2009-04-13 2014-08-19 Apceth Gmbh & Co. Kg Engineered mesenchymal stem cells and method of using same to treat tumors
KR101301262B1 (ko) 2009-10-23 2013-08-27 가톨릭대학교 산학협력단 ＴＧＦβ를 코딩하는 뉴클레오티드 서열이 도입된 간엽줄기세포 및 그의 용도
KR101622650B1 (ko) 2009-12-31 2016-06-01 엘지디스플레이 주식회사 액정 전계 렌즈 및 이를 이용한 입체 표시 장치
JP5804385B2 (ja) 2010-03-10 2015-11-04 株式会社ツーセル 間葉系幹細胞を含む細胞製剤及びその製造方法
WO2011153458A2 (en) 2010-06-03 2011-12-08 University Of Rochester Compositions and methods for inhibition of or treatment of dengue virus infection
US20130209427A1 (en) 2010-06-18 2013-08-15 Rajesh Thangapazham Hair follicle neogenesis
KR101309910B1 (ko) 2010-08-06 2013-09-17 이화여자대학교 산학협력단 대장암 진단 및 치료제로서의 신데칸-2 펩티드 단편
KR101317507B1 (ko) 2010-08-30 2013-10-15 가톨릭대학교 산학협력단 레바미피드를 유효성분으로 포함하는 암 또는 면역질환의 예방 또는 치료용 조성물
JP2014501110A (ja) * 2010-12-22 2014-01-20 ジ アドミニストレーターズ オブ ザ テュレーン エデュケーショナル ファンド 高い増殖能を有する多能性間葉系幹細胞の識別および培養のための方法
KR20120095022A (ko) 2011-02-18 2012-08-28 가톨릭대학교 산학협력단 간엽줄기세포 및 면역조절 ｔ 세포를 유효성분으로 포함하는 이식편대숙주질환 예방 또는 치료용 세포치료제 조성물
ES2629502T3 (es) 2011-03-11 2017-08-10 Children's Medical Center Corporation Métodos y composiciones relacionados con exosomas de células madre mesenquimales
KR101145406B1 (ko) * 2011-07-06 2012-05-15 (주)지노믹트리 장암 진단을 위한 장암 특이적 메틸화 마커 유전자의 메틸화 검출방법
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
WO2013134649A1 (en) * 2012-03-09 2013-09-12 Verastem, Inc. Biomarkers for cancer stem cells and related methods of use
SG11201407626QA (en) 2012-05-18 2014-12-30 Agency Science Tech & Res Umbilical cord mesenchymal stem cell exosomes
DK2983721T4 (da) 2013-04-12 2021-02-01 Evox Therapeutics Ltd Terapeutiske indgivelsesvesikler
AU2014255755B2 (en) 2013-04-16 2018-10-25 Orbsen Therapeutics Limited Medical use of syndecan-2
WO2015038075A1 (en) 2013-09-16 2015-03-19 Agency For Science, Technology And Research Method
WO2015088414A1 (en) 2013-12-13 2015-06-18 Isletone Ab Immunomodulatory compositions
CA2956987C (en) 2014-08-18 2023-03-21 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
WO2016063204A1 (en) 2014-10-20 2016-04-28 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
GB201418562D0 (en) 2014-10-20 2014-12-03 Univ London Queen Mary Peptides
WO2016154019A1 (en) 2015-03-20 2016-09-29 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
US11918687B2 (en) 2016-01-15 2024-03-05 Orbsen Therapeutics Limited SDC-2 exosome compositions and methods of isolation and use
CN113620950A (zh) 2016-02-19 2021-11-09 凤凰分子设计公司 可用作rsk抑制剂的羧酰胺衍生物
US20210154235A1 (en) 2017-05-30 2021-05-27 Orbsen Therapeutics Limited Stromal stem cell therapeutics and methods of use
WO2019012334A2 (en) 2017-07-14 2019-01-17 Orbsen Therapeutics Limited METHODS OF ISOLATION AND USE OF CD39 STROMAL STEM CELLS
BR112021000100A2 (pt) 2018-07-05 2021-03-30 Novobind Livestock Therapeutics Inc. Anticorpos contra agentes causadores de doença de aves domésticas e usos dos mesmos
EP4017512B1 (en) 2019-08-23 2025-04-02 Orbsen Therapeutics Limited Compositions for monocyte and macrophage polarization and methods of use

Also Published As

Publication number Publication date
US11884936B2 (en) 2024-01-30
US11230700B2 (en) 2022-01-25
US20230313142A1 (en) 2023-10-05
ES2959833T3 (es) 2024-02-28
US20160215265A1 (en) 2016-07-28
CN104302763A (zh) 2015-01-21
AU2013217870A1 (en) 2014-09-11
EP2902482B1 (en) 2018-09-19
EP3492584A1 (en) 2019-06-05
US20240209319A1 (en) 2024-06-27
US11434471B2 (en) 2022-09-06
US20230323307A1 (en) 2023-10-12
WO2013117761A1 (en) 2013-08-15
ES2697780T3 (es) 2019-01-28
US11926848B2 (en) 2024-03-12
US11952590B2 (en) 2024-04-09
US20220112466A1 (en) 2022-04-14
ES2539186T3 (es) 2015-06-26
EP2758523B1 (en) 2015-03-11
KR102124837B1 (ko) 2020-06-22
JP5829765B2 (ja) 2015-12-09
US11952589B2 (en) 2024-04-09
AU2013217870B2 (en) 2018-11-08
US20230332106A1 (en) 2023-10-19
BR112014019277A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-06-20
US10920197B2 (en) 2021-02-16
US20180298341A1 (en) 2018-10-18
PT2758523E (pt) 2015-07-21
SI2758523T1 (sl) 2015-10-30
PL2758523T3 (pl) 2015-08-31
EP4257203A2 (en) 2023-10-11
KR20140143363A (ko) 2014-12-16
HRP20150594T1 (hr) 2015-07-17
EP2758523A1 (en) 2014-07-30
US10907131B2 (en) 2021-02-02
US20150037292A1 (en) 2015-02-05
JP2015509360A (ja) 2015-03-30
CA2863821C (en) 2023-09-19
EP2902482A1 (en) 2015-08-05
EP4257203A3 (en) 2024-05-15
EP3492584B1 (en) 2023-07-19
BR112014019277A8 (pt) 2017-07-11
IN2014KN01777A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-10-23
HUE026480T2 (en) 2016-06-28
CY1116365T1 (el) 2017-02-08
CA2863821A1 (en) 2013-08-15
US20220090019A1 (en) 2022-03-24
RU2636551C2 (ru) 2017-11-23
CN104302763B (zh) 2017-08-29
RU2014136711A (ru) 2016-03-27
SMT201500147B (it) 2015-09-07
RS54073B1 (en) 2015-10-30
DK2758523T3 (da) 2015-06-22
US20200078413A1 (en) 2020-03-12
US11142747B2 (en) 2021-10-12

Similar Documents

Publication Publication Date Title
PL2758523T3 (pl) Zrębowe komórki macierzyste
SG11201500329WA (en) Stem cell microparticles
SG11201406336YA (en) Stem cell microparticles
SG10201702387YA (en) Cell lines
PL2844824T3 (pl) Trzpień uszczelniający
PT2785834T (pt) Composição de células estaminais melhorada
SG11201503579RA (en) Cell culture med
EP2893590A4 (en) SODIUM-HALOGEN SECONDARY CELL
AU347859S (en) Battery
AU346864S (en) Battery
SG11201500417PA (en) Cell culture
GB201411223D0 (en) None
EP2939306A4 (en) DRUMS
EP2760996A4 (en) SOMATIC STEM CELLS
EP2831949A4 (en) SODIUM OXYGEN CELLS
IL237228A0 (en) Stem cells that improve healing
GB2504996A8 (en) Stem cell culture method
IL239484A0 (en) Materials for omitting enterprise-tumor cells
SI2904319T1 (sl) Termostatski ventil
EP2939294A4 (en) DRUMS
GB2503032B (en) Serviceable bioreactor
GB201203255D0 (en) Valve
GB201211873D0 (en) Cell culture
HUP1200436A2 (en) Valve arrangement
EP2937605A4 (en) VALVE STRUCTURE

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)